Intermittent theta-burst stimulation (iTBS) as concomitant treatment for borderline personality disorder - a pilot study

Conditions

F60.31 F32

Milenko Kujovic, Christian Bahr, Mathias Riesbeck, Daniel Benz, Martina Deiß et al. (10 authors)

Borderline Personality Disorder and Emotion Dysregulation2025-01-141 citations

Effects of intermittent theta burst stimulation add-on to dialectical behavioral therapy in borderline personality disorder: results of a randomized, sham-controlled pilot trial

Milenko Kujovic, Christian Bahr, Mathias Riesbeck, Daniel Benz, Lena Wingerter et al. (10 authors)

European Archives of Psychiatry and Clinical Neuroscience2024-09-194 citations

10.1007/s00406-024-01901-0

Theta burst stimulation add on to dialectical behavioral therapy in borderline-personality-disorder: methods and design of a randomized, single-blind, placebo-controlled pilot trial

Milenko Kujovic, Daniel Benz, Mathias Riesbeck, Christian Bahr, Christian Kriegs et al. (12 authors)

European Archives of Psychiatry and Clinical Neuroscience2023-09-159 citations

10.1007/s00406-023-01692-w

Interventions

Group 1: Patients with a primary diagnosis of borderline personality disorder, who are receiving an inpatient, dialectical behavioural therapy based psychiatric treatment will be treated with intermit

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: - Borderline Personality Disorder (DSM V) assessed through a standardized clinical interview (SKID V PD) - sufficient knowledge of German - Age: 18-45 - No prior treatment with DBT - If medicated stable treatment with the medication for 2 weeks before commendement of the brain stimulation treatment. Medication should remain stable during the 4-weeks of brain stimulation. - Receiving inpatient or day-clinic, standardized, DBT-based treatment - Participants must be able to give consent to participate - Negative pregnancy test and being prepared to use contraception for the duration of brain stimulation treatment

Exclusion criteria

Exclusion criteria: - history of seizures or epilepsy - metallic implants of the skull - extensive tatoos on the head - significant brain tumors or brain malformations - cerebrovascular events - traumatic brain injury - neurodegenerative disorders - brain surgery - deep brain stimulation - Pacemaker - severe somatic disorders - other psychiatric comorbidities (measured by Mini-DIPS-OA) except Depression - acute suicidality (MADRS Score >4 for Item 10) - tinnitus - pregnancy - claustrophoby - treatment with antiepileptic drugs - taking benzodiazepines in doses exceeding 1mg Lorazepam per day - patients under legal guardianship who require their guardian's approval to provide consent - treatment with electroconvulsive therapy in the current episode - current or prior treatment with deep brain stimulation, vagus nerv stimulation or other intracranial implants

Design outcomes

Primary

Measure	Time frame
Improvements in borderline symptoms, reduction in impulsivity, changes in self-compassion measured using clinical questionnaires and cognitive tasks. These measures will be assessed before start of the stimulation, a number of measures weekly during the stimulation and all measures again at the end of the 4-weeks of stimulation.	—

Secondary

Measure	Time frame
Reduction in depressive symptoms, improvements in general functionality measured using clinical questionnaires that will be administered before starting the treatment, a number of measures weekly during the treatment, and all measures again at the end of the 4-week stimulation treatment. Additionally, an optional fMRI scan will be carried out before starting the stimulation to predict treatment response using machine-learning based analyses. Furthermore, blood samples will be taken before and after the 4 week stimulation treatment to measure changes in metanephrine and heart rate variability will also be assessed before and after the Treatment optionally.	—

Measure

Time frame

Reduction in depressive symptoms, improvements in general functionality measured using clinical questionnaires that will be administered before starting the treatment, a number of measures weekly during the treatment, and all measures again at the end of the 4-week stimulation treatment. Additionally, an optional fMRI scan will be carried out before starting the stimulation to predict treatment response using machine-learning based analyses. Furthermore, blood samples will be taken before and after the 4 week stimulation treatment to measure changes in metanephrine and heart rate variability will also be assessed before and after the Treatment optionally.

—

Countries

Germany

Contacts

Public ContactMilenko Kujovic

LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität

milenko.kujovic@lvr.de+49(211)922-2735

Outcome results

None listed